Efficacy of intravitreal ranibizumab (Lucentis®) injection for the treatment of macular edema secondary to retinal vein occlusion;Retina ven tikanikliǧina baǧli maküla ödeminin tedavisinde intravitreal ranibizumab (Lucentis®) enjeksiyonunun etkinliǧi

Retina-Vitreus

Volumn 19, Issue 2, 2011, Pages 108-112

  Eken, Volkan ^a   Batioǧlu, Figen ^a   Özmert, Emin ^a  

^a ANKARA UNIVERSITY   (Turkey)

Author keywords

Macular edema; Retina; VEGF; Vein

Indexed keywords

RANIBIZUMAB;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DRUG EFFICACY; HUMAN; INTRAOCULAR PRESSURE; OPTICAL COHERENCE TOMOGRAPHY; RETINA MACULA EDEMA; RETINA VEIN OCCLUSION; TREATMENT RESPONSE; VISUAL ACUITY;

EID: 79960999582     PISSN: 13001256     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Hayreh SS.: Classification of central retinal vein occlusion. Ophthalmology. 1983;90:458-474. (Pubitemid 13059774)
2. Central Vein Occlusion Study Group: Natural history and clinical management of central retinal vein occlusion. Arch Ophthalmol. 1997;115:486-491.
3. Klein R, Klein B, Moss SE, et al. The epidemiology of retinal vein occlusion: the beaver dam eye: Study. Trans Am Ophthalmol Soc. 2001;98:133-141.
4. Zhao J, Sastry SM, Sperduto RT, et al.: Arteriovenous crossing patterns in branch retinal vein occlusion. Ophthalmology. 1993;100:423-428. (Pubitemid 23088544)
5. Christoffersen NL, Larsen M.: Pathophysiology and hemodynamics of branch retinal vein occlusion. Ophthalmology. 1999;106:2054-62. (Pubitemid 30194224)
6. Klein R, Moss SE, Meuer SM, et al.: The 15-year cumulative incidence of retinal vein occlusion. Arch Ophthalmol. 2008;126:513-518. (Pubitemid 351549845)
7. McGrath MA, Wechsler F, Hunyor AB, et al.: Systemic factors contributory to retinal vein occlusion. Arch Intern Med. 1978;138:216-220. (Pubitemid 9003874)
8. The Eye Disease Case-Control Study Group.: Risk factors for central retinal vein occlusion. Arch Ophthalmol. 1996;114:545-554.
9. Eye Disease Case-Control Study Group.: Risk factors for branch retinal vein occlusion. Am J Ophthalmol. 1993;116:286-296.
10. The Branch Vein Occlusion Study Group.: Argon lazer photocoagulation for macular oedema in branch vein occlusion. Am J Ophthalmol. 1984;98:271-282.
11. The Central Vein Occlusion Study Group.: Evaluation of grid pattern photocoagulation for macular oedema in central vein occlusion. Ophthalmology. 1995;102:1425-1433.
12. Goff MJ, Jumper JM, Yang SS, et al.: Intravitreal triamcinolone acetonide treatment of macular edema associated with central retinal vein occlusion. Retina. 2006;26:896-901. (Pubitemid 44547442)
13. Williamson TH, O'Donnell A.: Intravitreal triamcinolone acetonide for cystoid macular edema in nonischemic central retinal vein occlusion. Am J Ophthalmol. 2005;139:860-866. (Pubitemid 40614773)
14. Pe'er J, Folberg R, Itin A, et al.: Vascular endothelial growth factor upregulation in human central retinal vein occlusion. Ophthalmology. 1998;105:412-416. (Pubitemid 28125092)
15. Noma H, Funatsu H, Yamasaki M, et al.: Pathogenesis of macular edema with branch retinal vein occlusion and intraocular levels of vascular endothelial growth factor and interleukin-6. Am J Ophthalmol. 2005;140:256-261.
16. Algvere PV, von Wendt G, Gudmundsson J, et al.: Visual improvement in central retinal vein occlusion (CRVO) following intravitreal injections of bevacizumab (Avastin). Acta Ophthalmol. 2009;7.
17. Jaissle GB, Leitritz M, Gelisken F, et al.: One-year results after intravitreal bevacizumab therapy for macular edema secondary to branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol. 2009;247:27-33.
18. Heier JS, Antosyzk AN, Pavan PR, et al.: Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose sturdy. Ophthalmology. 2006;113:1-4.
19. Park CH, Jaffe GJ, Fekrat S.: Intravitreal triamcinolone acetonide in eyes with cystoid macular edema associated with central retinal vein occlusion. Am J Ophthalmol. 2003;111:419-425. (Pubitemid 37101237)
20. Bashshur ZF, Ma'luf RN, Allam S, et al.: Intravitreal triamcinolone for the management of macular edema due to nonischemic central retinal vein occlusion. Arch Ophthalmol. 2004;122:1137-1140. (Pubitemid 39031128)
21. Jonas JB.: Intravitreal triamcinolone acetonide: a change in a paradigm. Ophthalmic Res. 2006;38:218-245. (Pubitemid 44213982)
22. Scott IU, Ip MS, Van Veldhuisen PC, et al.: A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular Edema secondary to branch retinal vein occlusion. Arch Ophthalmol. 2009;127:1115-1128.
23. Brown DM, Campochiaro PA, Singh RP, et al.: Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology. 2010;117:1124-1133.
24. Campochiaro PA, Heier JS, Feiner L, et al.: Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology. 2010;117:1102-1112.
25. Spaide RF, Chang LK, Klancnik JM, et al.: Prospective study of intravitreal ranibizumab as a treatment for decreased visual acuity secondary to central retinal vein occlusion. Am J Ophthalmol. 2009;147:298-306.
26. Matsumoto Y, Freund KB, Peiretti E, et al.: Rebound macular edema following bevacizumab (Avastin) therapy for retinal venous oclusive disease. Retina. 2007;27:426-431. (Pubitemid 46624281)
27. Noma H, Funatsu H, Mimura T, et al.: Vitreous levels of interleukin-6 and vascular endothelial growth factor in macular edema with central retinal vein occlusion. Ophthalmology. 2009;116:87-93.
28. Noma H, Funatsu H, Yamasaki M, et al.: Aqueous humour levels of cytokines are correlated to vitreous levels and severity of macular oedema in branch retinal vein occlusion. Eye. 2008;22:42-48.
29. Noma H, Minamoto A, Funatsu H, et al.: Intravitreal levels of vascular endothelial growth factor and interleukin-6 are correlated with macular edema in branch retinal vein occlusion. Graefes Arch Exp Ophthalmol. 2006;244:309-315.